3 results
Primary: Safety and tolerability of fingolimod 0,5 mg in a broader population of MS patients.Explorerend: incidence of macular edema, bradyarrythmia, Patient-Reported Outcomes Indices for Multiple Sclerosis (PRIMuS) and Short Form Health Survey*12 (…
Primary: Safety and tolerability of fingolimod 0,5 mg.Secundairy: Long-term efficacy.Exploratory: Patient-Reported Outcomes Indices for Multiple Sclerosis (PRIMuS) and Short Form Health Survey*12 (SF-12), Treatment Satisfaction Questionnaire for…
The study contains 2 parts: Part 1 is the dose escalation part. Part 2 is the dose expansion part.The primary objective of part 1 is to determine recommended Phase 2 dose(s) (RP2Ds) of JNJ-78278343 by investigating the incidence and severity of AEs…